

Peace Harbor Medical Center Outpatient Infusion Service Request

Phone: (541) 902-6019 Fax: (541) 902-1649

Thank you for selecting our infusion services team to care for your patient. If you are not a PeaceHealth provider, all information listed below is required before we can process orders and schedule your patient for treatment. Part A- Patient scheduling and contact information: Patient Name (Last, First): _______Date of Birth: _____ Patient Contact Information and Phone Number (s): Ordering Provider Name (Print): Provider Clinic or Service Address: ______ Clinic or Service Phone Number: _____ Clinic or Service Fax Number: _____ Diagnosis (include ICD 10 codes): Medication and Service Requested- list J-Code/ CPT code if known: ______ Date Service is Requested to Begin: ______ Date Service is Expected to End: ___ Order will expire 1 year from date of provider signature unless "date service is expected to end" is earlier. <u>Part B- Insurance and Prior Authorization.</u> Any non-PeaceHealth provider must obtain prior authorization prior to service. Attach a copy of authorization documentation received from insurance payer when submitting orders. Insurance (Payer) Company: Prior Authorization Number and Conditions: Prior Authorization Expiration Date: _____ Insurance (Payer) Contact Phone Number: <u>Part C-</u> Elements needed to guide medication therapy are included with request for service: All orders and instruction (please use the PeaceHealth approved ordering form) are complete and include provider signature AND printed name at the bottom of each order page. Check the boxes of ALL orders you would like to activate. For blood products, PeaceHealth Blood and Transfusion Consent form is signed and dated by the provider and the patient. If information is located outside of PeaceHealth's electronic medical record system attach the following: A list of current medications reconciled by patient provider is available and includes a list of known allergies. Recent progress notes from ordering provider. A copy of relevant laboratory results and other appropriate supporting documentation. **IMPORTANT MESSAGE TO PROVIDERS:** To reduce delays in treatment and phone calls to your office you may participate in the PHMC formulary process by signing this document. A clinical pharmacist will adjust orders according to PHMC approved policies and procedures. I agree to utilize PHMC policies & procedures that have been reviewed by the Pharmacy & Therapeutics Committee and authorized by the Medical Executive Committee of PHMC. This agreement will be issued for the duration of active orders contained within this treatment plan.

FAX completed service request and completed orders to: PHMC OP Infusion and Nursing Services 541-902-1649

PROVIDER SIGNATURE: ______ DATE: _____ TIME:_____





Accelerated InFLIXimab and Biosimilars Outpatient Infusion Therapy Plan Initiation and Maintenance

All Pre-Selected Boxed Orders Are Initiated by Default Unless Crossed Out by Practitioner. All Boxed Orders Require Practitioner Check to be Initiated.

Heading	Content				
	Provider Instruction –please review and address requirements for admission to service:				
Service	This plan is for patients that have completed at least 4 consecutive infusions of infliximab over				
	standard titration rate with no evidence of infusion reaction. Most recent titration to have been done				
	within 12 weeks of potential conversion.				
	2. Ordering physician/provider has screened this patient for history of chronic infection,				
	heart failure, seizure disorder, liver disease, tuberculosis, blood dyscrasias, hepatitis (hepatitis B				
	surface antigen and hepatitis B core antibody), or malignancy prior to initiation of InFLIXimab				
	(Remicade®) or biosimilar equivalent therapy. <i>Date of screening:</i>				
	3. Provide patient with the FDA approved medication guide for inFLIXimab.				
Supportive Care	Select One:				
	☐ InFLIXimab-dyyb (Inflectra) IV infusion (formulary preferred agent); or				
	☐ InFLIXimab-abda (Renflexis) IV infusion; or				
	☐ InFLIXimab (Remicade) IV infusion				
	Select Dose (dose will be rounded to nearest vial size):				
	<u>Weight-based Dose</u> Non <u>Weight-based Dose</u>				
	☐ 5 mg/kg ☐ mg (indicate dose)				
	☐ 3 mg/kg				
	mg/kg (indicate other dose)				
	Select Frequency:				
	For new patients beginning infliximab therapy:				
	☐ Initiation regimen administered at 0, 2 and 6 weeks <i>followed by</i> maintenance infusion every 8 weeks.				
	☐ Initiation regimen administered at 0, 2 and 6 weeks <i>followed by</i> maintenance infusion everyweeks.				
	For established patients on maintenance therapy:				
	☐ Maintenance infusion every 8 weeks				
	☐ Maintenance infusion every weeks (indicate frequency)				
	Additional order instruction:				
	☐ Use an in-line, sterile, non-pyrogenic, low protein-binding filter with 1.2-micron pore size or less.				
	Give premedication(s) 30 minutes prior to infusion (if applicable).				
	• Infuse 10 ml/hour x15 minutes; then 20 ml/hour x15 minutes; then 40 ml/hour x15 minutes; then				
	80 ml/hour x15 minutes; then 150 ml/hour x15 minutes; then max 250 ml/hour until done.				
	☑ INFUSIONS 5 through 8 - If first four infusions tolerated with no evidence of infusion reactions:				
	Infuse total volume over one hour.				
	☐ INFUSIONS 9 and subsequent- If all previous infusions tolerated with no evidence of infusion reactions:				
	Infuse total volume over 30 minutes.				

Practitioner Signature:Date o	of Order:Time:
-------------------------------	----------------

Final page of orders must include signature of the ordering practitioner, date, and time.





Accelerated InFLIXimab and Biosimilars Outpatient Infusion Therapy Plan Initiation and Maintenance

Heading	Orders Are Initiated by Default Unless Crossed Out by Practitioner. All <u>Boxed Orders</u> Require Practitioner Check to be Initiated. Content				
Nursing Orders	☐ Patient to complete at least 4 consecutive infusions of infliximab over the standard titration rate with				
runomig Grueno	no evidence of infusion reaction before converting to an accelerated rate infusion. Most recent titration				
	to have been done within 12 weeks of potential conversion.				
	to have been done within 12 weeks of potential conversion.				
	☑ For patients who have received their last infliximab infusion longer than 12 weeks ago, reinitiate				
	standard titration.				
	☐ For established accelerated infusion patients changing infliximab products, reinitiate standard titration.				
	 Infusion # 1-4: vitals prior to infusion, before each rate increase, 30 minutes following infusion. Observe patient 30 minutes after completion of infusion. 				
	• Infusion # 5-8: vitals prior to infusion, 30 minutes after initiation, at end of infusion, and 30				
	minutes following infusion. Observe patient 30 minutes after completion of infusion.				
	 Infusion #9: vitals prior to infusion, at end of infusion, and 30 minutes following infusion. Observe 				
	patient 30 minutes after completion of infusion.				
	Infusion #10 and beyond: vitals prior to infusion and end of infusion. No observation required				
	upon completion of infusion.				
Labs	☐ CBC with automated differential once prior to starting treatment.				
	☐ CBC with automated differential every weeks				
	☐ Comprehensive metabolic panel once prior to starting treatment.				
	☐ Comprehensive metabolic panel every weeks				
	☐ Treatment lab instructions – Provider approves to release and draw labs 2 days pre and post this				
	planned treatment date.				
Nursing IV	Select the most appropriate option below:				
Access and Maintenance	Insert PERIPHERAL IV as needed and flush (unless provider selects option for a central line).				
Maintenance					
	☐ Access and use NON-PICC Central Line/CVAD				
	☑ Initiate Central Line (non-PICC) maintenance protocol.				
	☑ Sodium chloride 0.9% (NS) flush 10 mL IV as needed for line care, before and after medication				
	administration, at discharge, and at de-access (sterile NS for Port-a-Cath access)				
	☑ Sodium chloride 0.9% (NS) flush 20 mL IV as needed for line care post lab draw.				
	☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐				
	☐ Alteplase (Cathflo) injection 2 mg intra-catheter as needed for occluded central line catheters- For				
	clearing central line catheter. Add 2.2 mL sterile water for injection to vial; let the vial stand				
	undisturbed to allow large bubbles to dissipate. Mix by gently swirling until completely dissolved				
	(complete dissolution should occur within 3 minutes); do not shake. Final concentration: 1mg/mL.				
	Instill medication in non-functional lumen. Do not use lumen while dwelling. Allow to dwell 30				

Practitioner Signature: __ Date of Order: Time:

Final page of orders must include signature of the ordering practitioner, date, and time.

Date of Revision: 09/2/2024 Page 3 of 5





Accelerated InFLIXimab and Biosimilars Outpatient Infusion Therapy Plan Initiation and Maintenance

All Pre-Selected Boxed Orders Are Initiated by Default Unless Crossed Out by Practitioner. All Boxed Orders Require Practitioner Check to be Initiated.

Heading	Content					
	minutes and check for patency by drawing back on lumen for blood return. If line is still not patent, allow medication to dwell an additional 90 minutes. Dwell time not to exceed 120 min. Use second dose of Alteplase (Cathflo) if catheter is not patent after 120 min. If the catheter is functional, aspirate and waste the medication and residual clot prior to flushing the line.					
	☐ Access and use PICC Central Line/CVAD					
	☐ Initiate PICC maintenance protocol.					
	□ Change PICC line dressing weekly and as needed.					
	Sodium chloride 0.9% (NS) flush 10 mL IV as needed for line care, and before and after medication administration.					
	☑ Sodium chloride 0.9% (NS) flush 20 mL IV as needed for line care post lab draw					
	□ Alteplase (Cathflo) injection 2 mg intra-catheter as needed for occluded central line catheters- For clearing central line catheter. Add 2.2 mL sterile water for injection to vial; let the vial stand undisturbed to allow large bubbles to dissipate. Mix by gently swirling until completely dissolved (complete dissolution should occur within 3 minutes); do not shake. Final concentration: 1mg/mL. Instill medication in non-functional lumen. Do not use lumen while dwelling. Allow to dwell 30 minutes and check for patency by drawing back on lumen for blood return. If line is still not patent, allow medication to dwell an additional 90 minutes. Dwell time not to exceed 120 min. Use second dose of Alteplase (Cathflo) if catheter is not patent after 120 min. If the catheter is functional, aspirate and waste the medication and residual clot prior to flushing the line.					
As Needed	Standard As Needed Medications:					
Medications	Sodium chloride 0.9% (NS) flush 10 mL IV as needed for line care.					
	Sodium chloride 0.9% 500 mL continuous infusion at 25 mL/hour IV as needed for therapy					
	administration (i.e., blood products, chemotherapy, potassium administration).					
Pre-	Acetaminophen (Tylenol) 650 mg PO once on arrival					
Medications	DiphenhydrAMINE (Benadryl) 25 mg PO once on arrival, OR					
	Loratadine (Claritin) 10 mg PO once on arrival					
	MethylPREDNISolone sodium succinate (Solu-MEDROL) 40 mg IV once on arrival					
Emergency Medications	If patient has symptoms of anaphylaxis (wheezing, dyspnea, hypotension, angioedema, chest pain, or tongue swelling), discontinue infusion and initiate standard emergency response procedures. Standard Emergency Medications:					
	☑ DiphenhydrAMINE (Benadryl) injection 25-50 mg IV once as needed for mild to moderate drug					
	reactions (flushing, dizziness, headache, diaphoresis, fever, palpitations, chest discomfort, blood					
	pressure changes (>/= 20 points in SBP), nausea, urticaria, chills, pruritis)					
	 Administer 50 mg IV if patient has NOT had diphenhydramine within 2 hours of reaction 					
	 Administer 25 mg IV if patient has had diphenhydramine within 2 hours of reaction, if reaction doesn't resolve in 3 minutes may repeat 25 mg IV dose for a total of 50 mg and contact provider. 					
	☐ Albuterol 90 mcg/actuation inhaler 2 puffs once as needed for wheezing, shortness of breath					
	associated with infusion reaction and contact provider.					
	☑ MethylPREDNISolone (Solu-Medrol) injection 125 mg IV once as needed for shortness of breath for					
	continued symptoms of mild to moderate drug reactions (flushing, dizziness, headache, diaphoresis, fever, palpitations, chest discomfort, blood pressure changes (>/= 20 points in SBP), nausea,					

rractitioner signature:nime:bate of Order:nime:	Practitioner Signature:		Date of Order:	Time	e:
---	--------------------------------	--	----------------	------	----

Final page of orders must include signature of the ordering practitioner, date, and time.





Accelerated InFLIXimab and Biosimilars Outpatient Infusion Therapy Plan Initiation and Maintenance

All <u>Pre-Selected Boxed Orders</u> Are Initiated by Default Unless Crossed Out by Practitioner. All <u>Boxed Orders</u> Require Practitioner Check to be Initiated.

Heading	Content					
	urticaria, chills, pruritis) that worsen or persist 5 minutes after administration of diphenhydramine					
	(Benadryl) and contact provider. ☑ EPINEPHrine (Adrenalin) injection 0.5 mg IM once as needed for severe drug reaction (flushing,					
	dizziness, headache, diaphoresis, fever, palpitations, chest discomfort plus blood pressure changes					
	(>/= 40 points in SBP), shortness of breath with wheezing and 02 Sat < 90% and contact provider.					
Referral						
PHMC	PROVIDER – PLEASE SIGN, DATE AND TIME ORDERS AND RETURN TO:					
Outpatient Infusion Contact Information	PeaceHealth Peace Harbor Medical Center Outpatient Infusion Services Department 400 Ninth Street, Florence, OR 97439 Contact Phone: 541-902-6019 and FAX 541-902-1649					
Authorization	Person giving verbal or telephone order:					
	Person receiving verbal or telephone order: Check to indicate verbal or telephone orders have been read back to confirm accuracy					

Practitioner Signature:	 	_Date of Order:	Time:

Final page of orders must include signature of the ordering practitioner, date, and time.